Study on survival time of patients with advanced lung cancer treated with serpatinib

Selpatinib, as a precision therapy targeting RET gene mutations, has shown significant efficacy in multiple studies. Especially in the LIBRETTO-431 trial, the median progression-free survival (PFS) of patients with advanced non-small cell lung cancer (NSCLC) in the serpatinib treatment group was significantly longer than that in the chemotherapy group. This result shows that serpatinib has a significant advantage in controlling disease progression, which may lead to longer survival time for patients.

In the LIBRETTO-431 trial, the median PFS was 24.8 months in the serpatinib arm, compared with 11.2 months in the chemotherapy arm. This means that more than half of patients treated with serpatinib survived more than 24.8 months before their disease worsened. In addition, serpatinib also performed well in terms of objective response rate (ORR), reaching 84%, which was much higher than the value in the chemotherapy group. These data provide strong treatment basis and hope for patients with advanced lung cancer.

It is important to emphasize that each patient's specific situation is unique, so the impact of serpatinib on survival time will vary among individual patients. Factors such as the patient's overall health, stage and type of disease, genetic mutations, and response to treatment may affect final survival time.

Although serpatinib is effective, it may also cause a series of side effects, such as high blood pressure and abnormal liver function. The severity and frequency of these side effects vary among individuals and require close monitoring and prompt management to ensure patient safety and treatment effectiveness.

Serpatinib shows great promise in extending survival time in patients with advanced lung cancer. However, the specific survival time is still affected by many factors and cannot be generalized. Patients should work closely with their medical team to develop a personalized treatment plan for optimal treatment results and quality of life.

References:

https://www.nice.org.uk/guidance/ta911/documents/674